Latest Us Market Expansion News

EBR Systems has locked in a three-year purchasing agreement with CHRISTUS Health, the ninth-largest US hospital network, to advance its WiSE CRT System's US rollout across 66 hospitals.

Serko Limited posted a 34% jump in total income to NZD 120.9 million for FY26, powered by strong Booking.com for Business growth and a full year of GetThere revenue. The company’s EBITDAFI surged 137%, while net loss narrowed. Serko.ai’s US closed beta marks a strategic pivot into AI-driven business travel.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

EBR Systems has landed a significant purchasing agreement with Advocate Health, the third-largest US non-profit health system, opening access for its WiSE wireless cardiac pacing technology across 69 hospitals in eight states.

Evion Group has secured an exclusive option to acquire a high-grade fluorspar project in Nevada, complementing its graphite assets and supported by a $6.5 million capital raise to fund US expansion and exploration.

Ionic Rare Earths’ subsidiary Ionic Technologies has led a pioneering UK project demonstrating a fully circular supply chain for electric vehicle magnets using 100% recycled rare earth oxides, achieving performance parity with primary materials and advancing UK critical minerals goals.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Ava Risk Group posted a $6.1 million Q3 sales intake and secured a $7 million strategic investment to fuel US expansion, while geopolitical tensions delay some Middle East orders.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.